The investigators refer to the trial with clinicaltrials.gov indentifier NCT02610933 entitled Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients. After termination of this trial, included patients will be asked to participate in the extension trial by continuing the treament of their respective allocation arm. No new intervention will be done.
The investigators refer to the trial with clinicaltrials.gov indentifier NCT02610933 entitled Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients. After termination of this trial, included patients will be asked to participate in the extension trial by continuing the treament of their respective allocation arm. No new intervention will be done. Relevant endpoints like death, cardiovascular events and bleeding episodes will be registered.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
132
replacement of warfarin by rivaroxaban
dietary supplement of vitamin K2 MK-7 2000µg thrice weekly
treatment with a vitamin K antagonist
OLV Hospital
Aalst, Belgium
composite of fatal and non-fatal stroke and other cardiovascular events
composite of fatal and non-fatal stroke and other cardiovascular events
Time frame: through study completion, on average 3 years
death rate
cause of death
Time frame: through study completion, on average 3 years
safety: incidence of life-threatening, major and minor bleeding
incidence of life-threatening, major and minor bleeding
Time frame: through study completion, on average 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.